Essex Bio-Technology (1061) H1 2025 earnings summary

Executive summary

• Revenue/turnover for the six months ended 30 June 2025 rose 5.8% year-over-year to HK$876.5 million, with net profit up 3.8% to HK$163.4 million.

• Ophthalmology and Surgical segments contributed 47.6% and 51.2% of turnover, respectively, with flagship biologics accounting for 83.5% of total turnover.

• R&D investment increased, with 18 programmes in pre-clinical to clinical stages and major late-stage assets in ophthalmology and oncology.

• Interim dividend of HK$0.07 per share declared, up from HK$0.06 last year.

• R&D investment increased to HK$66.5 million, focusing on ophthalmology and biologics pipeline.

Financial highlights

• Gross profit increased to HK$778.6 million from HK$738.8 million year-over-year; gross profit margin was 88.8% (down from 89.2%).

• Distribution and selling expenses rose 4.7% to HK$471.6 million; administrative expenses decreased 3% to HK$99.7 million.

• Cash and cash equivalents stood at HK$640.5 million as of 30 June 2025, up from HK$557.2 million at year-end 2024.

• Bank borrowings increased to HK$270.5 million, with a gearing ratio of 29.7%.

• Net profit margin was 18.6% (down from 19.0%).

Outlook and guidance

• Focus remains on expanding ophthalmology and surgical/biologics portfolios, with new product launches and clinical milestones expected.

• Ongoing construction of a second factory in Zhuhai, expected completion in 2026 or 2027.

• Continued investment in R&D and strategic collaborations to drive mid- and long-term growth.

• Management anticipates ongoing challenges from centralised procurement and drug price pressures in China.